Cerus Corporation to Participate in Stephens Annual Investment Conference

Rhea-AI Summary

Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Stephens Annual Investment Conference on December 3, 2021, at 2:00 p.m. ET in Nashville, Tennessee. A live webcast will be accessible on the Cerus Investor Relations page, with a replay available for about two weeks post-event. Cerus is focused on safeguarding the global blood supply, offering technologies like the INTERCEPT Blood System, which has CE Mark and FDA approval for pathogen reduction in platelets and plasma. For details, visit www.cerus.com/ir.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate in the Stephens Annual Investment Conference in Nashville, Tenn., on Friday, December 3, 2021 at 2:00 p.m. ET.

A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005018/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When is Cerus Corporation's CFO scheduled to speak at the Stephens Annual Investment Conference?

Kevin D. Green, CFO of Cerus Corporation, is scheduled to speak on December 3, 2021, at 2:00 p.m. ET.

Where will the Stephens Annual Investment Conference be held?

The conference will take place in Nashville, Tennessee.

How can I access the webcast of Cerus Corporation's event?

The live webcast can be accessed on the Cerus Investor Relations page at www.cerus.com/ir.

What products does Cerus Corporation focus on?

Cerus Corporation focuses on technologies for pathogen protection in blood components, notably the INTERCEPT Blood System.

What approvals does the INTERCEPT Blood System have?

The INTERCEPT Blood System for platelets and plasma has both CE Mark and FDA approval.